Pre-earnings brief
Reports
Wed, Nov 4, 2026
Est. EPS
—
Est. revenue
—
Implied move
±9.4%
EPS beat rate
88%
Teva Pharmaceutical Industries Limited is a global leader in generic and specialty pharmaceuticals, focusing on providing high-quality medications at affordable prices. As a key player in the health care sector, Teva's performance is closely watched due to its impact on drug accessibility and pricing in the pharmaceutical industry.
Last quarter
In Q2 2026, Teva reported an EPS of $0.02, falling short of expectations by 60%. Despite this miss, the stock rose 9.60% the following day, indicating some investor optimism.
EPS beat streak
0Q
EPS beat rate
88%
Avg EPS surprise
+6.79%
Avg 1-day reaction
+4.22%
Overall, analysts expect mixed results from Teva's upcoming earnings report, especially following a disappointing Q2. Investors will be keen to see if the company can rebound and meet or exceed expectations.
Bull case
If Teva can demonstrate strong revenue growth and improved profitability, it may restore investor confidence and lead to a significant stock price increase.
Bear case
Conversely, if the company reports another disappointing quarter, it could raise concerns about its long-term viability and lead to a sharp decline in stock price.
The print will turn on these.
Q1
What is the EPS for Q3-2026?
The EPS figure will be crucial in determining whether Teva has improved its profitability compared to last quarter.
Q2
How is Teva addressing competition in the generics market?
Understanding Teva's strategy in a competitive landscape will provide insights into its future growth potential.
—
Est. EPS
$-0.50
Est. Rev
$257M
Impl. Move
±7.5%
Why consensus could be wrong
The Street may underestimate Teva's ability to recover from its recent earnings miss, as the company's strong pipeline and cost management efforts could lead to better-than-expected results.
Supporting evidence
Teva has a history of beating EPS expectations 88% of the time, suggesting potential for a surprise.
The options market is pricing a significant move, indicating investor anticipation of volatility that could favor a positive outcome.
Key risk
If EPS exceeds $0.10, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is currently uncertain about Teva's ability to rebound from recent earnings disappointments, making this quarter critical.
Bull confirmed if
A significant EPS of $0.10 or higher would indicate strong operational performance.
Bear confirmed if
An EPS below $0.02 would confirm ongoing struggles and raise concerns about profitability.
What the market is pricing for the move.
Implied Move
±9.41%
Historical Avg
±9.5%
The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.
Options are pricing ±9.4% while TEVA has averaged ±9.5% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.4%
30d HV
29.6%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing in-line setup in Health Care
Fade rate: 13 of 30 (43%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 30 faded and 17 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.6%, with a raw directional average of +2.0% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
26.37%
of float
Insider
0.56%
of float
Holders
119
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
63,894,301 sh · $2.5B
5.48%
-1.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Teva beats expectations, history suggests a potential stock increase of around 3.45%, confirming a positive turnaround.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await clearer guidance.
Miss
Should Teva miss again, history suggests a decline of approximately 9.60%, reinforcing concerns about its performance.
The lines on the call that would change the story.
Harel Insurance Investments & Financial Services Ltd.
48,138,805 sh · $1.9B
4.13%
4.8%
Phoenix Financial Ltd.
42,933,367 sh · $1.7B
3.68%
0.4%
WCM Investment Management, LLC
41,315,232 sh · $1.6B
3.55%
1.2%
Clal Insurance Enterprises Holdings Ltd
40,596,506 sh · $1.6B
3.48%
5.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.